Related Experiment Video
Updated: Feb 2, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
A Pilot Clinical Study of Liquid Ubiquinol Supplementation on Cardiac Function in Pediatric Dilated Cardiomyopathy
Fong-Lin Chen1,2,3, Po-Sheng Chang4,5, Yi-Chin Lin6
1Department of Pediatrics, Chung Shan Medical University Hospital, Taichung 40201, Taiwan. cshy053@gmail.com.
Insights
Liquid ubiquinol supplementation improved cardiac function in children with pediatric dilated cardiomyopathy (PDCM). This hydrophilic nutrient increased coenzyme Q10 levels, enhancing ejection fraction and fractional shortening, and reducing heart failure symptoms.
Area of Science:
- Cardiology
- Pediatrics
- Nutritional Science
Background:
- Pediatric dilated cardiomyopathy (PDCM) is a severe cardiac condition in children.
- Ubiquinone (CoQ10) is vital for cellular energy production.
- A new hydrophilic ubiquinol supplement offers potential therapeutic benefits.
Purpose of the Study:
- To evaluate the impact of liquid ubiquinol on cardiac function in children with PDCM.
- To assess changes in New York Heart Association (NYHA) classification.
- To correlate plasma coenzyme Q10 levels with cardiac performance.
Main Methods:
- Ten children with PDCM received liquid ubiquinol (10 mg/kg/day) for 24 weeks.
- Cardiac function assessed via echocardiography (EF, FS).
- NYHA classification and plasma coenzyme Q10 levels were monitored.
Main Results:
- Ejection fraction (EF) and fractional shortening (FS) significantly improved up to week 16.
- Higher plasma coenzyme Q10 correlated with better EF and FS.
- 30% of participants showed improved NYHA functional classification after 24 weeks.
Conclusions:
- Liquid ubiquinol supplementation effectively increases coenzyme Q10 levels in children with PDCM.
- Supplementation demonstrates a positive effect on cardiac function (EF, FS).
- Ubiquinol may ameliorate heart failure symptoms in pediatric patients.
Background:
Pediatric dilated cardiomyopathy (PDCM) is a life-threatening type of cardiac muscle dysfunction in children. Ubiquinone is a lipid-soluble nutrient that participates in energy synthesis. Recently, a novel hydrophilic ubiquinol supplement was developed. The purpose of this study was to assess the effect of liquid ubiquinol supplementation (10 mg/kg body weight/day) on cardiac function in children with PDCM.
Methods:
Ten children diagnosed with PDCM were recruited to this study and administered with liquid ubiquinol for 24 weeks. The cardiac function was measured by echocardiography. The New York Heart Association (NYHA) functional classification was used to assess symptoms of heart failure. Plasma coenzyme Q10 levels were measured during the study.
Results:
Ejection fraction (EF) and fractional shortening (FS) were significantly higher than the baseline values until week 16 of supplementation. Subjects who had higher plasma coenzyme Q10 concentration had significantly better EF and FS values. In addition, 30% of the subjects showed improvement in the NYHA classification after 24 weeks of supplementation.
Conclusion:
Liquid ubiquinol supplementation is associated with an increase the level of coenzyme Q10 to complementary improve cardiac function (particularly EF and FS) and ameliorate the symptoms of heart failure in children with PDCM.
More Related Videos
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Pilot and Numeric Relaying
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification

